29 January 2025
RUA Life
Sciences Plc
("RUA Life Sciences",
the "Company" or the
"Group")
New Supply
Agreement
RUA Life Sciences (AIM: RUA),
the holding company of a group of medical device businesses focused
on the exploitation of the world's leading long-term implantable
biostable polymer (Elast-Eon™), announces supply agreement within
its Medical Device and Components business unit with initial annual
value of over £500,000.
Further to the textile processing
project announced on 24 July last year, RUA has now entered a
multi-year supply contract with the global customer. The agreement
covers two product lines, unit volumes and unit pricing. The
revenue expected during the current calendar year is anticipated to
grow over time with a potential value over a five-year period of
£3.3 million. This new contract represents a six-fold increase on
the level of business undertaken for the customer prior to
commencing work on the project.
Bill Brown, CEO of RUA Life Sciences,
stated: "The RUA Quality, R&D and
Production teams worked closely with our global customer to exceed
their expectations during the project phase which resulted with
this long term partnership."
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For
further information contact:
|
RUA
Life Sciences
Bill Brown, CEO
Lachlan Smith, CFO
|
Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073
|
|
Cavendish Capital Markets
Limited
(Nominated Adviser and Broker)
Giles Balleny/Dan
Hodkinson (Corporate Finance)
Charlie
Combe (Broking)
Michael
Johnson (Sales)
|
Tel: +44 (0)20 7220 0500
|
About RUA Life Sciences
The RUA Life
Sciences group was created in April
2020 when RUA Life Sciences Plc (formerly known
as AorTech International Plc) acquired RUA Medical
Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the
Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives
of millions of patients by enabling medical devices with
Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or
component, or developing next generation medical devices,
a RUA Life Sciences business is pursuing our
vision.
Elast-Eon™'s biostability is
comparable to silicone while exhibiting excellent mechanical, blood
contacting and flex-fatigue properties. These polymers can be
processed using conventional thermoplastic extrusion and moulding
techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units
are:
|
RUA
Contract Manufacture:
|
End-to-end contract developer and
manufacturer of medical devices and implantable fabric
specialist.
|
|
RUA
Biomaterials:
|
Licensor of
Elast-EonTM polymers to the medical device
industry.
|
|
RUA
Vascular:
|
Commercialisation of open surgical
vascular grafts and patches
|
|
RUA
Structural Heart:
|
Development of polymeric leaflet
systems for heart valves.
|
